Study of Immunotherapy to Treat Advanced Prostate Cancer

BMS CA184-043: A phase 3 trial comparing ipilimumab vs. placebo following radiotherapy in patients with castrate-resistant prostate cancer (CRPC) that have received prior treatment with docetaxel:

Bristol-Myers Squibb (BMS) is conducting a Phase 3 trial using a novel immunotherapy agent in patients with metastatic CRPC that have received prior treatment with docetaxel.  Ipilimumab (anti CTLA-4) plus radiotherapy will be compared to placebo plus radiotherapy in this randomized, double-blind study, to determine if ipilimumab prolongs survival in men who have metastatic CRPC.

This study, which is currently recruiting patients, is being conducted in over 50 centers across the USA and also in 24 other countries around the world. The study is listed on the federal clinical trials website: www.clinicaltrials.gov under CT Identifier NCT00861614. (Go to http://www.clinicaltrials.gov/ct2/show/NCT00861614?term=NCT00861614&rank=1)